156 results on '"Grover, Shilpa"'
Search Results
2. Outcomes of High-Grade Immune Checkpoint Inhibitor Hepatitis in Hospitalized and Nonhospitalized Patients
3. Gastroparesis Following Immune Checkpoint Inhibitor Therapy: A Case Series
4. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
5. Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors
6. Characterizing germline APC and MUTYH variants in Ashkenazi Jews compared to other individuals
7. Prognostic Value of Inflammatory Bowel Disease-associated Biomarkers in Patients With Immune Checkpoint Inhibitor Enterocolitis: A Retrospective Cohort Study.
8. Correction to: Gastroparesis Following Immune Checkpoint Inhibitor Therapy: A Case Series
9. S226 Genetic Risk for Colorectal Cancer Is Associated With Earlier Onset and Higher Incidence of Immune Checkpoint Inhibitor Colitis
10. Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy
11. High Prevalence of Gastrointestinal Manifestations of COVID-19 Infection in Hospitalized Patients With Cancer
12. Evaluation and Surveillance Strategies for Patients at Increased Risk of Pancreatic Cancer
13. Screening for Pancreatic Cancer in High-risk Populations
14. Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Acute Pancreatitis
15. Racial variation in frequency and phenotypes of APC and MUTYH mutations in 6,169 individuals undergoing genetic testing
16. Continuing Medical Education Questions: March 2023
17. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course
18. S65 Distinct Imaging Patterns of Immune Checkpoint Inhibitor-Induced Acute Pancreatitis
19. Multiple high-grade and rare immune-related adverse events in a colon cancer patient with genomic and cytokine profiling
20. Su1249: CANCER OUTCOMES IN PATIENTS TREATED WITH BIOLOGICS FOR THE TREATMENT OF STEROID-REFRACTORY IMMUNE CHECKPOINT INHIBITOR COLITIS
21. Su1246: PREDICTORS OF NEED FOR BIOLOGIC THERAPY IN IMMUNE CHECKPOINT INHIBITOR COLITIS
22. Tu1172: CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF IMMUNE CHECKPOINT INHIBITOR GASTRITIS IN PATIENTS WITH CANCER
23. Su1275 IMMUNE CHECKPOINT INHIBITOR ESOPHAGITIS: TREATMENT OUTCOMES AND COMPLICATIONS
24. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
25. Utility of Liver Biopsy in Diagnosis and Management of High-grade Immune Checkpoint Inhibitor Hepatitis in Patients With Cancer
26. S109 Pancreatic Insufficiency and Time to Disease Progression Following Immune Checkpoint Inhibitor Pancreatic Injury in Advanced Cancers
27. S194 Prognostic Value of IBD-Associated Genetic Variants in Patients With Immune Checkpoint Inhibitor (ICI) Enteritis/Colitis
28. S1653 Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Pancreatitis
29. S195 Initial Pattern of Colitis Is Associated With Disease Outcomes in Patients With Immune Checkpoint Colitis
30. 236 EFFECT OF CORTICOSTEROID DOSING ON OUTCOMES IN HIGH-GRADE IMMUNE CHECKPOINT INHIBITOR HEPATITIS
31. 235 LIVER BIOPSY IS OF LIMITED UTILITY IN THE DIAGNOSIS AND MANAGEMENT OF IMMUNE CHECKPOINT INHIBITOR HEPATITIS IN CANCER PATIENTS
32. Sa284 ETIOLOGY AND OUTCOMES OF PANCREATIC ENZYME ELEVATIONS WITH THE USE OF IMMUNE CHECKPOINT INHIBITORS IN ADVANCED CANCERS
33. Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors
34. Esophagitis dissecans superficialis with immune checkpoint inhibitor therapy
35. Cover
36. Tu1146 GERMLINE AND SOMATIC VARIANTS ASSOCIATED WITH IMMUNE-CHECKPOINT INHIBITOR RELATED COLITIS
37. Checkpoint inhibitor induced esophagitis with documented resolution on infliximab
38. Medication‐specific variations in morphological patterns of injury in immune check‐point inhibitor‐associated colitis
39. 481 Impact of COVID-19 on Cancer Patients Receiving Immune Checkpoint Inhibitors
40. High Prevalence of Gastrointestinal Manifestations of COVID-19 Infection in Hospitalized Patients With Cancer
41. S0255 High Prevalence of Gastrointestinal Manifestations of COVID-19 Infection in Hospitalized Patients With Cancer
42. Outcomes after resumption of immune checkpoint inhibitor therapy after high‐grade immune‐mediated hepatitis
43. Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis
44. Management of immunotherapy colitis: Special considerations in the COVID‐19 era
45. Correction to: Gastroparesis Following Immune Checkpoint Inhibitor Therapy: A Case Series
46. Gastroparesis Following Immune Checkpoint Inhibitor Therapy: A Case Series
47. Characterizing germline APC and MUTYH variants in Ashkenazi Jews compared to other individuals
48. Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service
49. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis
50. Multidisciplinary team management for high grade immune-related adverse events (irAEs): A single center experience.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.